Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Mus musculus

ABSTRACT: Transcriptomic analysis in murine mammary carcinoma tissue after treatment with control vehicle or abemaciclib

PROVIDER: PRJNA387163 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR5575240.fastq.gz	Fastqsanger.gz
	SRR5575250.fastq.gz	Fastqsanger.gz
	SRR5575241.fastq.gz	Fastqsanger.gz
	SRR5575251.fastq.gz	Fastqsanger.gz
	SRR5575242.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 23

Similar Datasets

Transcriptomic analysis in murine mammary carcinoma tissue after treatment with control vehicle or abemaciclib

Project description:We measured changes in expression of 3,826 genes in MMTV-rtTA/tetO-HER2 mammary carcinoma tissue after treatment with control vehicle or abemaciclib

2017-08-17 | GSE99061 | GEO

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [MCF7 ATACseq]

Project description:We performed the Assay for Transposase-Accessible Chromatin with Sequencing (ATAC-Seq) on (i) parental MCF7 cells treated with control vehicle or abemaciclib (ii) abemaciclib- and abemaciclib/fulvestrant-resistant cells treated with control vehicle or INX-315.

2023-11-22 | GSE243147 | GEO

RNA-seq of BJ human fibroblasts treated with doxorubicin or abemaciclib compared to vehicle-treated counterpart

Project description:This experiment follows the transcriptional response of human fibroblasts (BJ) to two different drug treatments (doxorubicin and abemaciclib) in comparison to treatment with vehicle (water). The two drugs are used in cancer care and their mechanism of action entails proliferative arrest. Doxorubicin is a member of the anthracycline family and acts as a topoisomerase II inhibitor. Abemaciclib is an inhibitor of the Cyclin Dependent Kinases (CDK) 4/6 which arrest cell cycle at the G1/S phase.

2021-11-29 | E-MTAB-7642 | biostudies-arrayexpress

Therapeutic efficacy of INX-315, a selective CDK2 inhibitor, in solid tumors [HER2mouse resistant RNAseq]

Project description:We treated tumour-bearing MMTV-rtTA/tetO-HER2 female mice with 75 mg/kg Abemaciclib for ~4 weeks (or until point of resistance, where tumours have started to grow again). Mice were then divided into treatment groups, receiving vehicle (veh), INX-315 (INX), Abemaciclib (LY) or both INX-315 and Abema in combination (LY.INX). Resistant tumors were collected and RNA sequencing performed.

2023-11-22 | GSE243148 | GEO

Mus musculus

Project description:Mouse mammary epithelial and stromal cells: Hormone Treated vs. Vehicle Control

| PRJNA255598 | ENA

Tissue Proteomics of Feline Mammary Carcinoma: Different in protein profiles among Histological Grades using Liquid chromatography‑Tandem Mass Spectrometry

Project description:Mammary carcinomas are aggressive neoplasms and a significant cause of mortality in female cats. Despite surgical removal, feline mammary carcinoma (FMC) often recurs or metastasizes. Specific tumour biomarkers are necessary for early detection, prognosis, and therapy selection. This study aims to identify candidate biomarkers for FMC by comparing tissue proteomic profiles among grades of 31 FMC cats and 6 normal mammary tissues (control) using liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS).

2024-08-13 | PXD054830 | JPOST Repository

Mus musculus

Project description:Gene Expression of murine mammary stem-like cells, HC11: Control vs miRNA206 mimic treatment

| PRJNA306723 | ENA

Mus musculus

Project description:Murine hindlimb tissue: ischemic vs. control

| PRJNA267000 | ENA

Mus musculus

Project description:Mouse cardiac tissue: Vehicle treated control vs. 15mg/kg doxorubicin

| PRJNA123293 | ENA

Mus musculus

Project description:Mouse cardiac tissue: Vehicle treated control vs. 25mg/kg DMNQ